Title:
【発明の名称】脳のグルコース利用の増進
Document Type and Number:
Japanese Patent JP2002532416
Kind Code:
A
Abstract:
Brain glucose utilization can be increased by administering an agent that improves central nervous system insulin sensivity. By improving the central nervous system insulin sensivity and increasing brain glucose utilization, age-related memory loss and dementia can be prevented and/or reduced. The improvement in brain glucose utilization is independent of treatment for Type II diabetes. Among the central nervous system insulin sensitizers that can be administered to increase brain glucose utilization are thiazolidinediones, including troglitazone, rosiglotazone and pioglitazone. Other useful compounds include oxyzolidinediones, including JPP501, and non-chiral acyclic agents, including GL 262370, and substituted 4-hydroxy-phenylalcanoic acid derivatives which are PPAR gamma receptor activators. All of these agents act on the nuclear receptor PPAR gamma. In a preferred embodiment, the agents are administered in the form of prodrugs which are designed to cross the blood brain barrier.
Inventors:
Chain, Daniel Gee
Mike
Mike
Application Number:
JP2000587758A
Publication Date:
October 02, 2002
Filing Date:
December 17, 1999
Export Citation:
Assignee:
MINDSET BIOPHARMACEUTICALS(USA),INC.
International Classes:
C07D263/44; A61K9/50; A61K31/00; A61K31/192; A61K31/205; A61K31/221; A61K31/421; A61K31/427; A61K45/00; A61K45/06; A61K47/36; A61K47/42; A61K47/48; C07D417/06; C07D417/12; F42C15/26; (IPC1-7): A61K45/00; A61K9/50; A61K31/192; A61K31/205; A61K31/221; A61K31/421; A61K31/427; A61K45/06; A61K47/36; A61K47/42; A61K47/48
Attorney, Agent or Firm:
Hajime Tsukuni (1 person outside)